Oncology reports最新文献_第9页

Emerging role of sirtuins in non‑small cell lung cancer (Review). sirtuins在非小细胞肺癌中的新作用（综述）。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-02 DOI: 10.3892/or.2024.8786

Min Zhou, Lin Wei, Renfu Lu

引用次数: 0

[Retracted] LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑HSPA9. [撤稿】LOXL1-AS1通过调控miR-525-5p-HSPA9促进胸腺瘤和胸腺癌的发展。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.3892/or.2024.8789

Jin Wang, Haihua Huang, Xiaomiao Zhang, Haitao Ma

{"title":"[Retracted] LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑HSPA9.","authors":"Jin Wang, Haihua Huang, Xiaomiao Zhang, Haitao Ma","doi":"10.3892/or.2024.8789","DOIUrl":"10.3892/or.2024.8789","url":null,"abstract":"Following the publication of the above article, a concerned reader drew to the Editor's attention that certain of the cell invasion assay data featured in Figs. 2G and H, 5M and N, and 9K and L, and the tumor images shown in Fig. 6B, were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had either already been published elsewhere prior to the submission of this paper to Oncology Reports, or were under consideration for publication at around the same time (some of which have been retracted). In view of the fact that certain of these data had already apparently been published prior to the submission of this article for publication, the Editor of Oncology Reports has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 45: 117, 2021; DOI: 10.3892/or.2021.8068].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis. 组蛋白去乙酰化酶抑制剂和 PD-1 阻断剂通过促进 T 细胞浸润和凋亡，协同抑制小鼠模型中 B 细胞淋巴瘤的进展。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.3892/or.2024.8792

Tong Wang, Xu Ye, Hao Jiang, Yu Gao

{"title":"Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis.","authors":"Tong Wang, Xu Ye, Hao Jiang, Yu Gao","doi":"10.3892/or.2024.8792","DOIUrl":"10.3892/or.2024.8792","url":null,"abstract":"B‑cell lymphoma is difficult to cure because of its biological and clinical heterogeneity, and due to native chemoresistance. Immunotherapies that overcome cancer‑induced immune evasion have been the center of recent developments in oncology. This is emphasized by the accomplishment of various agents that disrupt programmed cell death protein 1 (PD‑1)‑mediated immune suppression in diverse tumors. However, while PD‑1 blockade has been effective in numerous malignancies, a significant proportion of cancers, including B‑cell lymphoma, show certain rates of primary resistance to these therapeutic strategies. Histone deacetylase inhibitors (HDACis) have exhibited anticancer activity though suppressing cell proliferation, inducing differentiation and triggering apoptosis. The present study aimed to explore a therapeutic strategy combining a HDACi (romidepsin) and PD‑1 blockade (BMS‑1) in B‑cell lymphoma, utilizing a constructed mouse model of B‑cell lymphoma. The IC50 of the two inhibitors was confirmed by MTT assay, and their inhibitory effects were revealed to be dose‑ and time‑dependent. The data demonstrated that the combined treatment of romidepsin and BMS‑1 synergistically inhibited the growth of B‑cell lymphoma. Furthermore, it was revealed that romidepsin and BMS‑1 synergistically triggered apoptosis in mouse B‑cell lymphoma. The synergistic effect of these agents was capable of activating tumor‑infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The results of the present study underscore the potential of HDAC inhibition in conjunction with PD‑1 blockade as a novel therapeutic approach for B‑cell lymphoma, highlighting the synergistic effects of these two mechanisms in enhancing antitumor immunity.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Corrigendum] Ethyl gallate suppresses proliferation and invasion in human breast cancer cells via Akt‑NF‑κB signaling. [更正] 没食子酸乙酯通过 Akt-NF-κB 信号抑制人类乳腺癌细胞的增殖和侵袭。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-02 DOI: 10.3892/or.2024.8787

Hongxia Cui, Jiaxin Yuan, Xiaohui Du, Ming Wang, Liling Yue, Jicheng Liu

{"title":"[Corrigendum] Ethyl gallate suppresses proliferation and invasion in human breast cancer cells via Akt‑NF‑κB signaling.","authors":"Hongxia Cui, Jiaxin Yuan, Xiaohui Du, Ming Wang, Liling Yue, Jicheng Liu","doi":"10.3892/or.2024.8787","DOIUrl":"10.3892/or.2024.8787","url":null,"abstract":"Following the publication of this article, an interested reader drew to the authors' attention that, for the cell migration assay data shown in Fig. 3C on p. 1287, the '2.5 μg/ml' and '5.0 μg/ml' panels appeared to be overlapping, such that these data were apparently derived from the same original source where they were intended to show the results from differently performed experiments. Upon asking the authors to provide an explanation, after having referred back to their original data, the authors realized that they had made an inadvertent error in assembling this figure. The revised version of Fig. 3, now showing the correct data for the '5.0 μg/ml' experiment, is shown on the next page. Note that the error made in assembling the data in Fig. 3 did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree to the publication of this corrigendum. The authors regret that this error went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. They also apologize to the readership for any inconvenience caused. [Oncology Reports 33: 1284‑1290, 2015; DOI: 10.3892/or.2014.3682].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling. [撤稿】lncRNA-u50535通过激活CCL20/ERK信号促进肺癌进展。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-02 DOI: 10.3892/or.2024.8785

Wei Wei, Xiaoliang Zhao, Jianquan Zhu, Lianmin Zhang, Yulong Chen, Bin Zhang, Yue Li, Meng Wang, Zhenfa Zhang, Changli Wang

引用次数: 0

[Corrigendum] Hispolon inhibits breast cancer cell migration by reversal of epithelial‑to‑mesenchymal transition via suppressing the ROS/ERK/Slug/E‑cadherin pathway. [更正] 希波龙通过抑制 ROS/ERK/Slug/E-cadherin 通路逆转上皮细胞向间质转化，从而抑制乳腺癌细胞迁移。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.3892/or.2024.8793

Zhao Zhao, Yi-Sheng Sun, Wei Chen, Long-Xian Lv, Yong-Quan Li

{"title":"[Corrigendum] Hispolon inhibits breast cancer cell migration by reversal of epithelial‑to‑mesenchymal transition via suppressing the ROS/ERK/Slug/E‑cadherin pathway.","authors":"Zhao Zhao, Yi-Sheng Sun, Wei Chen, Long-Xian Lv, Yong-Quan Li","doi":"10.3892/or.2024.8793","DOIUrl":"10.3892/or.2024.8793","url":null,"abstract":"Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, with the cell migration assay data shown in Fig. 7 on p. 901, the \"TPA\" and \"TPA + U0126\" panels were strikingly similar, such that data which were intended to show the results from differently performed experiments had apparently been derived from the same original source. In addition, it was noted that the \"TPA + hispolon\" and \"TPA + NAC\" data panels in Fig. 4B on p. 899 contained overlapping sections. Thirdly, a data panel was shared between Figs. 1 and 4, although this was intentional on the part of the authors as the same experiment was being portrayed in these figures. The authors were able to re‑examine their original data files, and realized that errors were made in asssembling Figs. 4B and 7. The revised versions of Figs. 4 and 7, now containing the correct data for the \"TPA + NAC\" experiment in Fig. 4B and the Control (\"Ctrl\") experiment in Fig. 7, are shown on the next two pages. The authors wish to emphasize that the corrections made to these figures do not affect the overall conclusions reported in the paper, and they are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this corrigendum. All the authors agree to the publication of this corrigendum, and also apologize to the readership for any inconvenience caused. [Oncology Reports 35: 896‑904, 2016; DOI: 10.3892/or.2015.4445].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 in vitro and in vivo. [更正] 达沙替尼和康柏西汀A-4在体外和体内的联合应用增强了抗肿瘤活性。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-07-26 DOI: 10.3892/or.2024.8783

Chong Zhang, Shuang-Shuang Zhou, Xiang-Rong Li, Bao-Ming Wang, Neng-Ming Lin, Lin-Yi Feng, Da-Yong Zhang, Li-Huang Zhang, Un-Bo Wang, Jian-Ping Pan

{"title":"[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‑4 in vitro and in vivo.","authors":"Chong Zhang, Shuang-Shuang Zhou, Xiang-Rong Li, Bao-Ming Wang, Neng-Ming Lin, Lin-Yi Feng, Da-Yong Zhang, Li-Huang Zhang, Un-Bo Wang, Jian-Ping Pan","doi":"10.3892/or.2024.8783","DOIUrl":"10.3892/or.2024.8783","url":null,"abstract":"Following the publication of this article, an interested reader drew to the authors' attention that the flow cytometric (FCM) plots in Fig. 2A on p. 2278 showing the 'Dasatinib' and 'CA‑4' experiments were duplicates of each other. After having re‑examined their original data, and due to the overall similarity of the data, the authors have realized that these data were inadvertently assembled incorrectly in the figure. They realize that they also made a further mistake regarding the writing of the ratios of mitochondrial membrane‑depolarized HO‑8910 cells for these FCM plots (essentially, these were written the wrong way around): The percentage of mitochondrial membrane‑depolarized HO‑8910 cells should have been written as 22.50% for the dasatinib‑treated cells (the centre‑left FCM plot) and 15.71% for the CA‑4‑treated cells (centre‑right plot). A revised version of Fig. 2 now showing alternative data for the FCM experiments shown in Fig. 2A, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2A did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. Furthermore, they apologize to the readership for any inconvenience caused. [Oncology Reports 29: 2275‑2282, 2013; DOI: 10.3892/or.2013.2405].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epithelial‑derived head and neck squamous tumourigenesis (Review). 上皮源性头颈部鳞状肿瘤发生（综述）。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-10-01 Epub Date: 2024-09-02 DOI: 10.3892/or.2024.8800

Charles Adolfu Shirima, Coralia Bleotu, Demetrios A Spandidos, Adel K El-Naggar, Gratiela Gradisteanu Pircalabioru, Ioannis Michalopoulos

{"title":"Epithelial‑derived head and neck squamous tumourigenesis (Review).","authors":"Charles Adolfu Shirima, Coralia Bleotu, Demetrios A Spandidos, Adel K El-Naggar, Gratiela Gradisteanu Pircalabioru, Ioannis Michalopoulos","doi":"10.3892/or.2024.8800","DOIUrl":"10.3892/or.2024.8800","url":null,"abstract":"Head and neck squamous cell carcinomas (HNSCCs), a heterogeneous group of cancers that arise from the mucosal epithelia cells in the head and neck areas, present great challenges in diagnosis, treatment and prognosis due to their complex aetiology and various clinical manifestations. Several factors, including smoking, alcohol consumption, oncogenic genes, growth factors, Epstein‑Barr virus and human papillomavirus infections can contribute to HNSCC development. The unpredictable tumour microenvironment adds to the complexity of managing HNSCC. Despite significant advances in therapies, the prediction of outcome after treatment for patients with HNSCC remains poor, and the 5‑year overall survival rate is low due to late diagnosis. Early detection greatly increases the chances of successful treatment. The present review aimed to bring together the latest findings related to the molecular mechanisms of HNSCC carcinogenesis and progression. Comprehensive genomic, transcriptomic, metabolomic, microbiome and proteomic analyses allow researchers to identify important biological markers such as genetic alterations, gene expression signatures and protein markers that drive HNSCC tumours. These biomarkers associated with the stages of initiation, progression and metastasis of cancer are useful in the management of patients with cancer in order to improve their life expectancy and quality of life.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological functions and potential mechanisms of miR‑143‑3p in cancers (Review). miR-143-3p 在癌症中的生物功能和潜在机制（综述）。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI: 10.3892/or.2024.8772

Jia Wu, Ying Zhu, Dandan Liu, Qingwei Cong, Changchuan Bai

{"title":"Biological functions and potential mechanisms of miR‑143‑3p in cancers (Review).","authors":"Jia Wu, Ying Zhu, Dandan Liu, Qingwei Cong, Changchuan Bai","doi":"10.3892/or.2024.8772","DOIUrl":"10.3892/or.2024.8772","url":null,"abstract":"In recent years, microRNAs (miRNAs or miRs) have been increasingly studied for their role in cancer and have shown potential as cancer biomarkers. miR‑143‑3p and miR‑143‑5p are the mature miRNAs derived from pre‑miRNA‑143. At present, there are numerous studies on the function of miR‑143‑3p in cancer progression, but there are no systematic reviews describing the function of miR‑143‑3p in cancer. It is widely considered that miR‑143‑3p is downregulated in most malignant tumors and that upstream regulators can act on this gene, which in turn regulates the corresponding target to act on the tumor. In addition, miRNA‑143‑3p can regulate target genes to affect the biological process of tumors through various signaling pathways, such as the PI3K/Akt, Wnt/β‑catenin, AKT/STAT3 and Ras‑Raf‑MEK‑ERK pathways. The present review comprehensively described the biogenesis of miR‑143‑3p, the biological functions of miR‑143‑3p and the related roles and mechanisms in different cancer types. The potential of miR‑143‑3p as a biomarker for cancer was also highlighted and valuable future research directions were discussed.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] LINC00665 functions as a competitive endogenous RNA to regulate AGTR1 expression by sponging miR‑34a‑5p in glioma. [撤稿】LINC00665 作为一种竞争性内源性 RNA，通过海绵状 miR-34a-5p 在胶质瘤中调控 AGTR1 的表达。

IF 3.8 3区医学

Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI: 10.3892/or.2024.8773

Yongyue Dai, Yucheng Zhang, Maolin Hao, Renwu Zhu

{"title":"[Retracted] LINC00665 functions as a competitive endogenous RNA to regulate AGTR1 expression by sponging miR‑34a‑5p in glioma.","authors":"Yongyue Dai, Yucheng Zhang, Maolin Hao, Renwu Zhu","doi":"10.3892/or.2024.8773","DOIUrl":"10.3892/or.2024.8773","url":null,"abstract":"Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that the 'Control' data panel shown for the EdU assay experiment in Fig. 6D on p. 1209 was strikingly similar to a data panel featured in Fig. 7 that had already been submitted to the journal Cancer Management and Research by different authors at different research institutes [Chen T‑J, Gao F, Yang T, Li H, Li Y, Ren H and Chen M‑W: Knockdown of linc‑POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Cancer Manag Res 12: 4379‑4390, 2020]. Owing to the fact that contentious data in the above article had already been submitted for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 45: 1202‑1212, 2021; DOI: 10.3892/or.2021.7949].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0